The Global Drug sales of Proquad, M-M-R Ii And Varivax stood at USD 2,241 Millions in 2022
The indicator recorded a historical decline (CAGR) of0.50% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Measles [strain Enders Edmonston], Mumps [strain Jeryl Lynn (Level B)], Rubella [strain Wistar RA 27/3] and Varicella [strain Oka/Merck]) vaccine (ProQuad) is an acrive immunizing preparation containing the components of M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblast and Varicella Virus Vaccine Live (Oka/Merck), the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells. It is formulated as lyophilized powder for suspension for subcutaneous or intramuscular route of administration.
ProQuad is marketed for the treatment of several indications in Infectious Disease therapy areas.
ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.
ProQuad was first approved in 2005 and is sold globally including the US, the UK, France, Germany, and Australia by Merck & Co Inc, and its subsidiaries. ProQuad drug sales recorded a low-double digit Year on Year growth in 2022. ProQuad drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
Mechanism of Action
ProQuad works by teaching the immune system (the body’s natural defences) how to defend itself against a disease. ProQuad contains small amounts of weakened forms of the viruses that cause measles, mumps, rubella, and chickenpox. When a person is given the vaccine, the immune system recognizes the weakened viruses as foreign and makes antibodies against them. In the future, the immune system will be able to produce antibodies quicker when it is again exposed to the viruses. The antibodies will help to protect against diseases caused by these viruses.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward